I
Immunovant, Inc. (IMVT)
NMS – Real Time Price. Currency in USD
38.85
+0.61 (1.60%)
At close: Jun 26, 2026, 4:00 PM EDT
38.84
-0.01 (-0.03%)
After-hours: Jun 26, 2026, 5:32 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
38.85
+0.61 (1.60%)
At close: Jun 26, 2026, 4:00 PM EDT
38.84
-0.01 (-0.03%)
After-hours: Jun 26, 2026, 5:32 PM EDT
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Tiago M. Girao CPA | Chief Financial Officer |
| Ms. Christine Blodgett | Senior Vice President of Human Resources |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-20 | 8-K | imvt-20260520.htm |
| 2026-05-20 | 10-K | imvt-20260331.htm |
| 2026-02-06 | 10-Q | imvt-20251231.htm |
| 2025-12-12 | 8-K | d68980d8k.htm |
| 2025-12-11 | 8-K | d760155d8k.htm |
| 2025-11-21 | 8-K | imvt-20251121.htm |
| 2025-11-10 | 8-K | imvt-20251110.htm |
| 2025-09-03 | 8-K | imvt-20250903.htm |
| 2025-08-28 | 8-K | imvt-20250827.htm |
| 2025-08-11 | 8-K | imvt-20250811.htm |